Long-term dual antiplatelet therapy and nuisance bleeding: impact on quality of life

Immagine di <a href="https://it.freepik.com/foto-gratuito/uomo-che-rimuove-la-benda-medica-bianca-sul-polso-sanguinante_3688336.htm#query=bleeding&position=18&from_view=search&track=sph">Freepik</a>
Submitted: September 24, 2022
Accepted: November 14, 2022
Published: November 18, 2022
Abstract Views: 1420
PDF: 342
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Long term dual antiplatelet therapy (LTDAPT), with ticagrelor 60 mg and low-dose aspirin, is indicated after acute coronary syndrome (ACS) for the secondary prevention of atherothrombotic events in high-risk patients with a history of ACS of at least 1 year. LTDAPT had a good tolerability and safety profile, but the risk of TIMI major bleeding was increased. However, even non-significant bleeding may be important because it has an effect on the quality of life and therefore may lead to treatment discontinuation. We, therefore, evaluated patients' experiences with LTDAPT and the impact of nuisance bleeding on quality of life and treatment adherence. We retrospectively reviewed 225 patients in follow-up after ACS with at least one high-risk condition, treated with ticagrelor 60 mg twice daily (after 90 mg twice daily for 12 months). The outpatient follow-up program after hospitalization provides a visit on day 30 after discharge, then after 3 months, continuing with six-monthly checks. We assessed the presence and intensity of bleeding, as well as health-related quality of life (HRQoL), at each visit. The TIMI score was used to determine the severity of the bleeding. Any overt bleeding event that did not meet the major and minor criteria was labeled "minimal" and could be framed as "nuisance bleeding." The HRQoL was assessed by the EuroQol-5 and Dimension (EQ-5D) visual analog scale (VAS) score. Minimal bleedings were present in 49 patients (21%), but only in one case (by decision of the patient) there was a cause for discontinuation of therapy. However, 39 (79%) subjects had asked for opinions on stopping the therapy during the telephone consultation. Factors influencing LTDAPT knowledge included access to medication counselling, engaging with information communicated during medication counselling, and access to timely, relevant and expert information and advice after discharge from the hospital. All adverse events, judged to be "not serious" in trials, may have an effect on the quality of life and therefore may lead to treatment discontinuation. The authors underline the importance of careful outpatient follow-up and ongoing counselling, to check out compliance and possible adverse effect of LTDAPT.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Bonaca MP, Bhatt DL, Cohen M, et al. For the PEGASUS –TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791-800. DOI: https://doi.org/10.1056/NEJMoa1500857
Dellborg M, Bonaca MP, Storey RF, et al. Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European Label: insights from PEGASUS-TIMI 54. Eur Heart J Cardiovasc Pharmacother 2019;5:200-6. DOI: https://doi.org/10.1093/ehjcvp/pvz020
Al-Salama ZT, Keating GM, Keam SJ. Ticagrelor: A review in long term secondary prevention of cardiovascular events. Drugs 2017;77:2025–36. DOI: https://doi.org/10.1007/s40265-017-0844-8
Graipe A, Söderström L, Mooe T. Increased use of ticagrelor after myocardial infarction not associated with Intracranial hemorrhage. Results from a Nationwide Swedish Registry. Stroke 2018;49:2877-82. DOI: https://doi.org/10.1161/STROKEAHA.118.022970
Pithara C, Pufulete M, Johnson TW, Redwood S. Patient perspectives of nuisance bleeding and adherence to dual antiplatelet therapy: a qualitative study. Open Heart 2020;7:e001405. DOI: https://doi.org/10.1136/openhrt-2020-001405
Huber CA, Meyer MR, Steffel J, et al. Post-myocardial infarction (MI) care: medication adherence for secondary prevention after MI in a large real-world population. Clin Ther 2019;41:107–17. DOI: https://doi.org/10.1016/j.clinthera.2018.11.012
Czarny MJ, Nathan AS, Yeh RW, et al. Adherence to dual antiplatelet therapy after coronary stenting: a systematic review. Clin Cardiol 2014;37:505–13. DOI: https://doi.org/10.1002/clc.22289
Kimble LP, Momary KM, Adewuyi M. A qualitative study of nuisance bleeding and medication-related beliefs with dual antiplatelet drug therapy. Heart Lung 2018;47:485-8. DOI: https://doi.org/10.1016/j.hrtlng.2018.05.014
Turgeon RD, Koshman SL, Dong Y, Graham MM. P2Y12 inhibitor adherence trajectories in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prognostic implications. Eur Heart J 2022;43:2303-13. DOI: https://doi.org/10.1093/eurheartj/ehac116
Kourbelis CM, Marin TS, Foote J, et al. Effectiveness of discharge education strategies versus usual care on clinical outcomes in acute coronary syndrome patients: a systematic review. JBI Evid Synth 2020;18:309–31. DOI: https://doi.org/10.11124/JBISRIR-D-19-00042
Biscaglia S, Tonet E, Pavasini R, et al. A counseling program on nuisance bleeding improves quality of life in patients on dual antiplatelet therapy: A randomized controlled trial. PLoS One 2017;12:e0182124. DOI: https://doi.org/10.1371/journal.pone.0182124
Keenan J. Improving adherence to medication for secondary cardiovascular disease prevention. Eur J Prev Cardiol 2017:24:s29–35. DOI: https://doi.org/10.1177/2047487317708145
Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials. A consensus report from the Bleeding Academic Research Consortium. Circulation 2011;123:2736-47. DOI: https://doi.org/10.1161/CIRCULATIONAHA.110.009449
Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337-43. DOI: https://doi.org/10.3109/07853890109002087
Bonaca MP, Bhatt DL, Ophuis TO, et al. Long-term tolerability of ticagrelor for the secondary prevention of major adverse cardiovascular events. A secondary analysis of the PEGASUS –TIMI 54 Trial. JAMA Cardiol 2016;1:425-32. DOI: https://doi.org/10.1001/jamacardio.2016.1017
Cesaro A, Taglialatela V, Gragnano F, et al. Low-dose ticagrelor in patients with high ischemic risk and previous myocardial infarction: a multicenter prospective real-world observational study. J Cardiovasc Pharmacol 2020;76:173–80. DOI: https://doi.org/10.1097/FJC.0000000000000856
Ratti G, Lizzadro A, Biglietto E, et al. Long term dual antiplatelet therapy for secondary prevention: management model and our experience. Eur Heart J 2020;22:G205-6.
Ratti G, Maglione A, Biglietto E, et al. Long term dual antiplatelet therapy after myocardial infarction: retrospective analysis in an outpatient population. Monaldi Arch Chest Dis 2021;92:1881. DOI: https://doi.org/10.4081/monaldi.2021.1881
Amin AP, Bachuwar A, ReidKJ, et al. Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status. J Am Coll Cardiol 2013;61:2130–8. DOI: https://doi.org/10.1016/j.jacc.2013.02.044
Bonaca MP, Bhatt DL, Steg PG, et al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J 2016;37:1133–42. DOI: https://doi.org/10.1093/eurheartj/ehv531
Laufs U, Rettig-Ewen V, Bohm M. Strategies to improve drug adherence. Eur Heart J 2011;32:264–8. DOI: https://doi.org/10.1093/eurheartj/ehq297

How to Cite

Ratti, Gennaro, Cinzia Monda, Federica Ratti, Marco Golino, Ludovica Fulgione, Cosimo Fulgione, Mario Mallardo, and Paolo Tammaro. 2022. “Long-Term Dual Antiplatelet Therapy and Nuisance Bleeding: Impact on Quality of Life”. Monaldi Archives for Chest Disease 93 (4). https://doi.org/10.4081/monaldi.2022.2437.

Similar Articles

<< < 1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.